In this study, we identified a considerable number of CLDN18.2-positive cases with stages II-III GC, indicating the possibility of a broader patient population who could potentially benefit from targeted treatments in both adjuvant and neoadjuvant contexts. The gene discussed is CLDN18; the disease is gastric cancer.